Shots:
- The companies collaborate to develop IN-006 (an inhaled form of regdanvimab) to treat patients with COVID-19. The results are expected in 2022
- Inhalon will start a P-I study of nebulized regdanvimab in the next few mos. & plans to complete at the end of 2021 while the study is funded by $7M from the US AMRDC. Celltrion has completed a P-III study which demonstrates that regdanvimab reduced the risk of hospitalization or death by 72% for patients with COVID-19 & 70% for all patients
- Additionally, in vitro & in vivo pre-clinical studies showed that CT-P59 strongly binds to SARS-CoV-2 RBD & neutralizes wild type & mutant variants of concern including Alpha variant
Click here to read full press release/ article | Ref: PR Newswire | Image: PR Newswire
The post Celltrion Collaborates with Inhalon to Develop Regdanvimab (CT-P59) for the Treatment of COVID-19 at Home first appeared on PharmaShots.
